Dr. Welling on SIRT in Patients With Hepatobiliary Neoplasms

Video

Theodore H. Welling MD, associate professor, department of Surgery, director, Liver Tumor Program, NYU Langone’s Perlmutter Cancer Center, discusses the use of selective internal radiation therapy (SIRT) in patients with hepatobiliary cancers.

Theodore H. Welling MD, associate professor, department of Surgery, director, Liver Tumor Program, NYU Langone’s Perlmutter Cancer Center, discusses the use of selective internal radiation therapy (SIRT) in patients with hepatobiliary cancers.

Physicians are still learning about the full advantages of SIRT. Ablative strategies in general have a role in the treatment of patients with hepatobiliary cancer, says Welling. Physicians are still identifying what combination of modalities, including thermal ablation techniques such as microwave radiofrequency, result in the best ablative approach in conjunction with surgery.

The field is still evolving with respect to highly selective radio embolization for either hepatic metastases or primary liver cancers. There is greater experience with primary liver cancers, states Welling, but physicians are starting to see more tailored approaches for hepatic metastases as well.

Related Videos
Kateryna Fedorov, MD, assistant professor, hematology-oncology, Vanderbilt University Medical Center
Lauren E. Nye, MD, breast medical oncologist, clinical medical director, Breast Cancer Prevention, the University of Kansas Cancer Center
Joseph G. Jurcic, MD
Zeynep Eroglu, MD
Video 10 - "Monitoring and AE Management Strategies with Fruquintinib in CRC"
Video 9 - "FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC"
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai